<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "1: product candidates", fill: "#66023c"},
{source: "1: product candidates", target: "1: early stage", fill: "#66023c"},
{source: "1: early stage", target: "1: successfully", fill: "#66023c"},
{source: "1: successfully", target: "1: commercialize them", fill: "#66023c"},
{source: "1: commercialize them", target: "1: sufficient revenues", fill: "#66023c"},
{source: "1: sufficient revenues", target: "1: operations", fill: "#66023c"},
{source: "1: product candidates", target: "3: Phase III ", fill: "#a2add0"},
{source: "3: Phase III ", target: "3: United States ", fill: "#a2add0"},
{source: "3: United States ", target: "3: men with testosterone", fill: "#a2add0"},
{source: "3: men with testosterone", target: "3: deficiency", fill: "#a2add0"},
{source: "3: deficiency", target: "3: Phase II ", fill: "#a2add0"},
{source: "3: Phase II ", target: "3: uterine fibroids", fill: "#a2add0"},
{source: "3: uterine fibroids", target: "3: Phase IbII ", fill: "#a2add0"},
{source: "3: Phase IbII ", target: "3: endometriosis", fill: "#a2add0"},
{source: "3: Phase III ", target: "4: significant", fill: "#a50b5e"},
{source: "4: significant", target: "4: development", fill: "#a50b5e"},
{source: "4: development", target: "4: Contents ", fill: "#a50b5e"},
{source: "4: Contents ", target: "4: phentolamine", fill: "#a50b5e"},
{source: "4: phentolamine", target: "4: additional", fill: "#a50b5e"},
{source: "4: additional", target: "4: regulatory", fill: "#a50b5e"},
{source: "4: regulatory", target: "4: candidates", fill: "#a50b5e"},
{source: "4: significant", target: "5: depends primarily on", fill: "#c00"},
{source: "5: depends primarily on", target: "5: successfully", fill: "#c00"},
{source: "5: successfully", target: "5: clinical trials", fill: "#c00"},
{source: "5: clinical trials", target: "5: regulatory approvals", fill: "#c00"},
{source: "5: regulatory approvals", target: "5: commercialize", fill: "#c00"},
{source: "5: commercialize", target: "5: product candidates", fill: "#c00"},
{source: "5: depends primarily on", target: "29: successfully", fill: "#d6cadd"},
{source: "29: successfully", target: "29: development", fill: "#d6cadd"},
{source: "29: development", target: "29: Proellex Androxal ", fill: "#d6cadd"},
{source: "29: Proellex Androxal ", target: "29: phentolamine", fill: "#d6cadd"},
{source: "29: phentolamine", target: "29: regulatory", fill: "#d6cadd"},
{source: "29: regulatory", target: "29: establishing", fill: "#d6cadd"},
{source: "29: establishing", target: "29: manufacturing", fill: "#d6cadd"},
{source: "29: manufacturing", target: "29: capabilities", fill: "#d6cadd"},
{source: "29: capabilities", target: "29: collaborative", fill: "#d6cadd"},
{source: "29: collaborative", target: "29: arrangements", fill: "#d6cadd"},
{source: "29: arrangements", target: "29: activities", fill: "#d6cadd"},
{source: "29: successfully", target: "START_HERE", fill: "#d6cadd"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Application Software</td>
    </tr>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
    <tr>
      <td>Automobile Manufacturers</td>
    </tr>
    <tr>
      <td>Motorcycle Manufacturers</td>
    </tr>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
    <tr>
      <td>Health Care Facilities</td>
    </tr>
    <tr>
      <td>Construction and Engineering</td>
    </tr>
    <tr>
      <td>Construction Materials</td>
    </tr>
    <tr>
      <td>Construction and Farm Machinery and Heavy Trucks</td>
    </tr>
    <tr>
      <td>Independent Power Producers and Energy Traders</td>
    </tr>
    <tr>
      <td>Pharmaceuticals Biotechnology and Life Sciences</td>
    </tr>
    <tr>
      <td>Biotechnology</td>
    </tr>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Crime</td>
    </tr>
    <tr>
      <td>Material Aid</td>
    </tr>
    <tr>
      <td>Leadership</td>
    </tr>
    <tr>
      <td>Political reform</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Complain</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Human death</td>
    </tr>
    <tr>
      <td>Endorse</td>
    </tr>
    <tr>
      <td>Reward</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Pessimistic comment</td>
    </tr>
    <tr>
      <td>Request</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Acknowledge responsibility</td>
    </tr>
    <tr>
      <td>Host meeting</td>
    </tr>
    <tr>
      <td>Rally support</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Promise</td>
    </tr>
    <tr>
      <td>Threaten</td>
    </tr>
    <tr>
      <td>Sanction</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Halozyme">Halozyme</a></td>
      <td>Halozyme Therapeutics is an American biotechnology company that develops novel oncology therapies designed to target the tumor microenvironment and licenses a novel drug delivery technology through corporate partnerships.\nThe company was founded in 1998 and went public in 2004.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/MannKind_Corporation">MannKind Corporation</a></td>
      <td>MannKind Corporation is a biopharmaceutical company focusing on the discovery, development, and commercialization of therapeutic products for diseases such as diabetes and pulmonary arterial hypertension. Based in Danbury, Connecticut, the company was founded in February 1991.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Aerie_Pharmaceuticals">Aerie Pharmaceuticals</a></td>
      <td>Aerie Pharmaceuticals Inc. (Nasdaq: AERI) is a publicly traded, clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/MediGene">MediGene</a></td>
      <td>Medigene AG (FSE: MDG1, ISIN DE000A1X3W00, Prime Standard) is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany. Medigene is working on the development of immunotherapies to enhance T cell activity against solid cancers.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Medicago_Inc.">Medicago Inc.</a></td>
      <td>Medicago Inc. is a privately-owned Canadian biotechnology company focused on the discovery, development, and commercialization of virus-like particles using plants as "bioreactors" to produce proteins as candidate vaccines and medications.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bavarian_Nordic">Bavarian Nordic</a></td>
      <td>Bavarian Nordic A/S is a fully integrated biotechnology company focused on the development, manufacturing and commercialization of vaccines for infectious diseases and cancer immunotherapies. The company is headquartered in Hellerup, Denmark, with a manufacturing facility in Kvistgård, and an additional site in Hørsholm.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Takeda_Oncology">Takeda Oncology</a></td>
      <td>Takeda Oncology (originally Millennium Pharmaceuticals) is a biopharmaceutical company based in Cambridge, Massachusetts. It is a fully owned subsidiary of Takeda Pharmaceutical.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Phases_of_clinical_research">Phases of clinical research</a></td>
      <td>The phases of clinical research are the stages in which scientists conduct experiments with a health intervention to obtain sufficient evidence for a process considered effective as a medical treatment. For drug development, the clinical phases start with testing for safety in a few human subjects, then expand to many study participants (potentially tens of thousands) to determine if the treatment is effective.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Sustainable_development">Sustainable development</a></td>
      <td>Sustainable development is an organizing principle for meeting human development goals while also sustaining the ability of natural systems to provide the natural resources and ecosystem services on which the economy and society depend. The desired result is a state of society where living conditions and resources are used to continue to meet human needs without undermining the integrity and stability of the natural system.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arrested_Development">Arrested Development</a></td>
      <td>Arrested Development is an American television sitcom created by Mitchell Hurwitz, which originally aired on Fox for three seasons from  2003 to 2006, followed by a two-season revival on Netflix from 2013 to 2019. The show follows the Bluths, a formerly wealthy dysfunctional family.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Development/For!">Development/For!</a></td>
      <td>Development/For! (Latvian: Attīstībai/Par!, AP!) is a liberal political alliance in Latvia.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Research_and_development">Research and development</a></td>
      <td>Research and development (R&amp;D or R+D), known in Europe as research and technological development (RTD), is the set of innovative activities undertaken by corporations or governments in developing new services or products, and improving existing ones. Research and development constitutes the first stage of development of a potential new service or the production process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Management_development">Management development</a></td>
      <td>Management development is the process by which managers learn and improve their management skills.\n\n\n== Background ==\nIn organisational development, management effectiveness is recognized as a determinant of organisational success.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Software_development">Software development</a></td>
      <td>Software development is the process of conceiving, specifying, designing, programming, documenting, testing, and bug fixing involved in creating and maintaining applications, frameworks, or other software components. Software development involves writing and maintaining the source code, but in a broader sense, it includes all processes from the conception of the desired software through to the final manifestation of the software, typically in a planned and structured process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Business_development">Business development</a></td>
      <td>Business development entails tasks and processes to develop and implement growth opportunities within and between organizations. It is a subset of the fields of business, commerce and organizational theory.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Clinical_trial">Clinical trial</a></td>
      <td>Clinical trials are experiments or observations done in clinical research. Such prospective biomedical or behavioral research studies on human participants are designed to answer specific questions about biomedical or behavioral interventions, including new treatments (such as novel vaccines, drugs, dietary choices, dietary supplements, and medical devices) and known interventions that warrant further study and comparison.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/ClinicalTrials.gov">ClinicalTrials.gov</a></td>
      <td>ClinicalTrials.gov is a registry of clinical trials. It is run by the United States National Library of Medicine (NLM) at the National Institutes of Health, and is the largest clinical trials database, holding registrations from over 329,000 trials from 209 countries.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Adaptive_clinical_trial">Adaptive clinical trial</a></td>
      <td>An adaptive clinical trial is a dynamic clinical trial that evaluates a medical device or treatment by observing participant outcomes (and possibly other measures, such as side-effects) on a prescribed schedule, and, uniquely, modifying parameters of the trial protocol in accord with those observations. This is in contrast to traditional randomized clinical trials (RCTs) that are static in their protocol and do not modify any parameters until the trial is completed.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Randomized_controlled_trial">Randomized controlled trial</a></td>
      <td>A randomized controlled trial (or randomized control trial; RCT) is a form of scientific experiment used to control factors not under direct experimental control. Examples of RCTs are clinical trials that compare the effects of drugs, surgical techniques, medical devices, diagnostic procedures or other medical treatments.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Pragmatic_clinical_trial">Pragmatic clinical trial</a></td>
      <td>A pragmatic clinical trial (PCT), sometimes called a practical clinical trial (PCT), is a clinical trial that focuses on correlation between treatments and outcomes in real-world health system practice rather than focusing on proving causative explanations for outcomes, which requires extensive deconfounding with inclusion and exclusion criteria so strict that they risk rendering the trial results irrelevant to much of real-world practice.\n\n\n== Examples ==\nA typical example is that an anti-diabetic medication in the real world will often be used in people with (latent or apparent) diabetes-induced kidney problems, but if a study of its efficacy and safety excluded some subsets of people with kidney problems (to escape confounding), the study's results may not reflect well what will actually happen in broad practice.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Clinical_trials_in_India">Clinical trials in India</a></td>
      <td>Clinical trials in India refers to clinical research in India in which researchers test drugs and other treatments on research participants. NDCTR 2019 and section 3.7.1 to 3.7.3 of ICMR guidelines requires that all researchers conducting a clinical trial must publicly document it in the Clinical Trials Registry - India.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Monitoring_in_clinical_trials">Monitoring in clinical trials</a></td>
      <td>Clinical monitoring is the oversight and administrative efforts that monitor a participant's health and efficacy of the treatment during a clinical trial. Both independent and government-run grant-funding agencies, such as the National Institutes of Health (NIH) and the World Health Organization (WHO), require data and safety monitoring protocols for Phase I and II clinical trials conforming to their standards.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Clinical_trials_on_Ayurveda">Clinical trials on Ayurveda</a></td>
      <td>Clinical trials on Ayurveda refers to any clinical trials done on Ayurvedic treatment. Ayurveda is a traditional medicine system in India and like other cultural medical practices includes both conventional medicine and also complementary and alternative medicine.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Analysis_of_clinical_trials">Analysis of clinical trials</a></td>
      <td>The analysis of clinical trials involves many related topics including:\n\nthe choice of an estimand (measure of effect size) of interest that is closely linked to the objectives of the trial,\nthe choice and definition of analysis sets,\nthe choice of an appropriate statistical model for the type of data being studied,\nappropriate accounting for the treatment assignment process,\nhandling of missing data,\nhandling of multiple comparisons or endpoints,\naccounting for interim analyses and trial adaptations,\nand appropriate data presentation.One basic guidance document on this topic is the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use guidance E9.\n\n\n== Choice of analysis set ==\nFailure to include all participants in the analysis may bias the trial results.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Commercialization">Commercialization</a></td>
      <td>Commercialization or commercialisation is the process of introducing a new product or production method into commerce—making it available on the market. The term often connotes especially entry into the mass market (as opposed to entry into earlier niche markets), but it also includes a move from the laboratory into (even limited) commerce.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/The_Managed_Heart">The Managed Heart</a></td>
      <td>The Managed Heart: Commercialization of Human Feeling, by Arlie Russell Hochschild, was first published in 1983. A 20th Anniversary edition with a new afterword added by the author was published in 2003.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Commercial_use_of_space">Commercial use of space</a></td>
      <td>Commercial use of space is the provision of goods or services of commercial value by using equipment sent into Earth orbit or outer space.  This phenomenon – aka Space Economy (or New Space Economy) – is accelerating cross-sector innovation processes combining the most advanced space and digital technologies to develop a broad portfolio of space-based services.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Kendrick_Lamar">Kendrick Lamar</a></td>
      <td>Kendrick Lamar Duckworth (born June 17, 1987) is an American rapper, songwriter, and record producer. He is often cited as one of the most influential rappers of his generation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Commercialization_of_love">Commercialization of love</a></td>
      <td>The notion of commercialization of love, that is not to be confused with prostitution (the commercialization of sexual activity), involves the definitions of romantic love and consumerism.\n\n\n== Sociological development ==\nThe commercialization of love is the ongoing process of infiltration of commercial and economical stimuli in the daily life of lovers and the association of monetary and non-monetary symbols and commodities in the love relationships.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Commercial_software">Commercial software</a></td>
      <td>Commercial software, or seldom payware, is a computer software that is produced for sale or that serves commercial purposes. Commercial software can be proprietary software or free and open-source software.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Commercialization_of_the_Internet">Commercialization of the Internet</a></td>
      <td>The commercialization of the Internet refers to the creation and management of online services principally for financial gain. It typically involves the increasing monetization of network services and consumer products mediated through the varied use of Internet technologies.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacturing">Manufacturing</a></td>
      <td>Manufacturing is the creation or production of goods with the help of equipment, labor, machines, tools, and chemical or biological processing or formulation. It is the essence of secondary sector of the economy.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>ZONAGEN INC      ITEM 1A RISK FACTORS     Our <font color="blue">product <font color="blue">candidates</font></font> are at an <font color="blue">early stage</font> of <font color="blue">development</font>, and if we are     not able to <font color="blue">successfully</font> develop and <font color="blue"><font color="blue">commercialize</font> them</font>, we may not generate     <font color="blue">sufficient revenues</font> to continue our business <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We currently have only two <font color="blue">product <font color="blue">candidates</font></font> that are in clinical     trials, and our <font color="blue">phentolamine</font>-based products, VASOMAX, Bimexes and ERxin, on     <font color="blue">partial clinical</font> hold in the <font color="blue">United States </font>and under review in certain     non-<font color="blue">United States </font>countries</td>
    </tr>
    <tr>
      <td>Androxal is in a Phase III, 200-patient safety     study  in the <font color="blue">United States </font>for the treatment of <font color="blue">men with <font color="blue">testosterone</font></font>     <font color="blue">deficiency</font>, and Proellex is presently in a Phase II, 150-patient study in     the <font color="blue">United States </font>for the treatment of <font color="blue">uterine fibroids</font> and in a Phase Ib/II     study  in  Europe for the treatment of <font color="blue">endometriosis</font></td>
    </tr>
    <tr>
      <td>We have expended     <font color="blue">significant</font> time, money and effort in the <font color="blue">development</font> of Proellex, <font color="blue">Androxal     </font>                                   -12-       _________________________________________________________________    [60]Table of <font color="blue">Contents       </font>and  our <font color="blue">phentolamine</font> products, and we will have to spend considerable     <font color="blue">additional</font> time, money and effort before seeking <font color="blue">regulatory</font> approval to     market these <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>Our business <font color="blue">depends primarily on</font> our ability to <font color="blue">successfully</font> complete     <font color="blue"><font color="blue">clinical trial</font>s</font>, obtain required <font color="blue">regulatory</font> approvals and <font color="blue">successfully</font>     <font color="blue">commercialize</font> our <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>If we fail to <font color="blue">commercialize</font> one or     more of our <font color="blue">product <font color="blue">candidates</font></font>, we may be unable to <font color="blue">generate sufficient</font>     revenues to <font color="blue">attain <font color="blue">profitability</font></font> or continue our business <font color="blue">operations</font> and our     reputation in the industry and in the <font color="blue">investment community could likely</font> be     <font color="blue">significant</font>ly damaged, each of <font color="blue">which would</font> cause our stock price to decline</td>
    </tr>
    <tr>
      <td>Because the <font color="blue">data from preclinical studies</font> and early <font color="blue"><font color="blue">clinical trial</font>s</font> for our     <font color="blue">product <font color="blue">candidates</font></font> are not <font color="blue">necessarily</font> predictive of future results, we can     provide  <font color="blue">no assurances</font> that any of them will have favorable results in     <font color="blue"><font color="blue">clinical trial</font>s</font> or receive <font color="blue">regulatory</font> approval</td>
    </tr>
    <tr>
      <td>Before we can obtain <font color="blue">regulatory</font> approval for the <font color="blue">commercial sale</font> of any     <font color="blue">product candidate</font> that we wish to develop, we are required to complete     preclinical  <font color="blue">development</font>  and  extensive  <font color="blue"><font color="blue">clinical trial</font>s</font> in humans to     <font color="blue">demonstrate</font> its safety and efficacy</td>
    </tr>
    <tr>
      <td>Positive <font color="blue">data from preclinical studies</font>     or early <font color="blue"><font color="blue">clinical trial</font>s</font> should not be <font color="blue">relied upon as evidence</font> that those     studies  or  trials  will  produce  positive results, or that later or     larger-scale <font color="blue"><font color="blue">clinical trial</font>s</font> will succeed</td>
    </tr>
    <tr>
      <td>Initial <font color="blue"><font color="blue">clinical trial</font>s</font> for     <font color="blue">Proellex and Androxal</font> have <font color="blue">been conducted only</font> in small numbers of patients     that may not <font color="blue">fully represent</font> the <font color="blue">diversity present</font> in <font color="blue">larger populations</font>,     and thus the limited data we have obtained may not predict results from     studies in <font color="blue">larger numbers</font> of <font color="blue">patients drawn from</font> more <font color="blue">diverse populations</font>,     and <font color="blue">therefore may</font> not predict the ability of Proellex to treat uterine     fibroids and <font color="blue">endometriosis</font> <font color="blue">or Androxal </font>to treat <font color="blue">testosterone</font> <font color="blue">deficiency</font></td>
    </tr>
    <tr>
      <td>We     will be required to <font color="blue">demonstrate</font> through larger-scale <font color="blue"><font color="blue">clinical trial</font>s</font> that     these  product  <font color="blue">candidates</font> are safe and <font color="blue">effective</font> for use in a diverse     population before we can seek <font color="blue">regulatory</font> approvals for their commercial     sale</td>
    </tr>
    <tr>
      <td>There is typically an <font color="blue">extremely high rate</font> of <font color="blue">attrition from</font> the     failure of drug <font color="blue">candidates</font> proceeding through <font color="blue"><font color="blue">clinical trial</font>s</font></td>
    </tr>
    <tr>
      <td>We will also     be required to complete a <font color="blue">two year rat <font color="blue">carcinogenicity</font> study</font> before we are     permitted to file a <font color="blue">new drug <font color="blue">application</font></font>, or NDA, f<font color="blue">or Androxal </font>and Proellex</td>
    </tr>
    <tr>
      <td>If Proellex, Androxal, or any other potential future <font color="blue">product candidate</font> fails     to <font color="blue">demonstrate</font> sufficient safety and efficacy in any <font color="blue">clinical trial</font>, we     would  experience <font color="blue">potentially</font> <font color="blue">significant</font> delays in, or be required to     abandon, <font color="blue">development</font> of that <font color="blue">product candidate</font></td>
    </tr>
    <tr>
      <td>If we delay or abandon our     <font color="blue">development</font> efforts related to <font color="blue">Proellex or Androxal</font>, we may not be able to     generate <font color="blue">sufficient revenues</font> to continue <font color="blue">operations</font> or <font color="blue">become profitable</font></td>
    </tr>
    <tr>
      <td>If we fail to obtain the <font color="blue">capital <font color="blue">necessary</font></font> to fund our <font color="blue">operations</font>, we will     have to delay, reduce or eliminate our research and <font color="blue">development</font> programs or     <font color="blue"><font color="blue">commercialization</font> efforts</font></td>
    </tr>
    <tr>
      <td>We expect to make <font color="blue">additional</font> capital outlays and to increase operating     <font color="blue">expenditures</font>  over  the  <font color="blue">next several years</font> to support our preclinical     <font color="blue">development</font> and <font color="blue">clinical trial</font> <font color="blue">activities</font>, <font color="blue">particularly</font> <font color="blue">with respect</font> to     pivotal <font color="blue"><font color="blue">clinical trial</font>s</font> for <font color="blue">Proellex and Androxal</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">existing financial</font>     resources are expected to be sufficient to fund our <font color="blue">operations</font> through     <font color="blue">December </font>31, 2006, depending on the timing and success of our clinical     trials</td>
    </tr>
    <tr>
      <td><font color="blue">Therefore </font>we will need to seek <font color="blue">additional</font> funding through public or     <font color="blue">private <font color="blue">financings</font></font>, including equity or debt <font color="blue">financings</font>, and/or through     other means, including <font color="blue"><font color="blue">collaboration</font>s</font> and <font color="blue"><font color="blue">license <font color="blue">agreement</font></font>s</font></td>
    </tr>
    <tr>
      <td>We do not know     whether <font color="blue">additional</font> financing will be available when needed, or that, if     available, we will obtain <font color="blue">financing on terms</font> favorable to our <font color="blue">stockholders</font>     or us</td>
    </tr>
    <tr>
      <td>If <font color="blue">adequate funds</font> are not available to us, we may be required to:       •   delay, reduce the scope of or <font color="blue">eliminate one</font> or more of our <font color="blue">development</font>     programs;         •   <font color="blue">relinquish</font>, license or <font color="blue">otherwise dispose</font> of rights to <font color="blue">technologies</font>,     <font color="blue">product <font color="blue">candidates</font></font> or products that we <font color="blue">would otherwise seek</font> to develop or     <font color="blue">commercialize</font>  <font color="blue">ourselves at</font> an <font color="blue">earlier stage</font> or on terms that are less     favorable <font color="blue">than might otherwise</font> be available; or         •   liquidate and dissolve our company</td>
    </tr>
    <tr>
      <td>Our <font color="blue">future capital <font color="blue">requirements</font> will depend upon</font> a number of factors,     including:       •   the size, complexity, results and timing of our <font color="blue">clinical programs</font>;         •   the cost to obtain <font color="blue">sufficient supply</font> of the <font color="blue">compounds <font color="blue">necessary</font></font> for     our <font color="blue">product <font color="blue">candidates</font></font> at a <font color="blue">reasonable cost</font>;         •   the time and <font color="blue">costs involved</font> in obtaining <font color="blue">regulatory</font> approvals;         •   the <font color="blue">costs involved</font> in preparing, filing , prosecuting, maintaining,     defending and <font color="blue">enforcing patent</font> claims; and         •   <font color="blue">competing <font color="blue">technological</font></font> and market <font color="blue">development</font>s</td>
    </tr>
    <tr>
      <td>These <font color="blue">factors could</font> result in <font color="blue">variations from</font> our currently projected     operating and <font color="blue">liquidity <font color="blue">requirements</font></font></td>
    </tr>
    <tr>
      <td>-13-       _________________________________________________________________    [61]Table of <font color="blue">Contents       </font>We have a history of operating losses, and we expect to <font color="blue">incur increasing net</font>     losses and may not achieve or maintain <font color="blue">profitability</font> for some time or at     all</td>
    </tr>
    <tr>
      <td>We have experienced <font color="blue">significant</font> operating losses in <font color="blue">each fiscal year</font>     since our inception</td>
    </tr>
    <tr>
      <td>As of <font color="blue">December </font>31, 2005, we had an <font color="blue">accumulated deficit</font>     of approximately dlra94dtta1 million</td>
    </tr>
    <tr>
      <td>We expect to <font color="blue">continue incurring net losses</font>     and may not achieve or maintain <font color="blue">profitability</font> for some time or at all</td>
    </tr>
    <tr>
      <td>As we     increase <font color="blue">expenditures</font> for clinical <font color="blue">development</font> of <font color="blue">Proellex and Androxal</font>, we     expect our operating losses to increase for at least the <font color="blue">next few years</font></td>
    </tr>
    <tr>
      <td>Our     ability  to  achieve <font color="blue">profitability</font> will depend, among other things, on     <font color="blue">successfully</font>  completing the <font color="blue">development</font> of Proellex, Androxal and our     <font color="blue">phentolamine</font> product family, obtaining <font color="blue">regulatory</font> approvals, <font color="blue">establishing</font>     marketing,  sales  and  <font color="blue">manufacturing</font>  <font color="blue">capabilities</font>  or  <font color="blue">collaborative</font>     <font color="blue"><font color="blue">arrangement</font>s</font>  with  others that possess such <font color="blue">capabilities</font>, and raising     sufficient funds to finance our <font color="blue">activities</font></td>
    </tr>
    <tr>
      <td>There can be no assurance that     we will be able to achieve <font color="blue">profitability</font> or that <font color="blue">profitability</font>, if achieved,     can be sustained</td>
    </tr>
    <tr>
      <td>Raising <font color="blue">additional</font> funds by issuing securities or <font color="blue">through <font color="blue">collaboration</font></font> and     licensing <font color="blue"><font color="blue">arrangement</font>s</font> may cause dilution to existing <font color="blue">stockholders</font>, restrict     our <font color="blue">operations</font> or require us to <font color="blue"><font color="blue">relinquish</font> propriety rights</font></td>
    </tr>
    <tr>
      <td>We  may  raise  <font color="blue">additional</font> funds through public or <font color="blue">private equity</font>     offerings,  debt  <font color="blue">financings</font> or corporate <font color="blue"><font color="blue">collaboration</font>s</font> and licensing     <font color="blue"><font color="blue">arrangement</font>s</font></td>
    </tr>
    <tr>
      <td>We cannot be certain that <font color="blue">additional</font> funding will be available     on acceptable terms, or at all</td>
    </tr>
    <tr>
      <td>To the extent that we raise <font color="blue">additional</font>     capital by issuing equity securities, our <font color="blue">stockholders</font>’ ownership will be     diluted</td>
    </tr>
    <tr>
      <td>Any  <font color="blue">debt financing</font> we <font color="blue"><font color="blue">enter into</font> may involve covenants</font> that     restrict our <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">restrictive covenants may</font> include <font color="blue">limitations</font>     <font color="blue">on borrowing</font> and <font color="blue">specific restrictions on</font> the use of our assets, as well as     <font color="blue">prohibitions on</font> our ability to create liens, pay dividends, redeem capital     stock or make <font color="blue">investments</font></td>
    </tr>
    <tr>
      <td>In addition, if we raise <font color="blue">additional</font> funds through     <font color="blue">collaboration</font> and licensing <font color="blue"><font color="blue">arrangement</font>s</font>, it may be <font color="blue">necessary</font> to <font color="blue">relinquish</font>     <font color="blue">potentially</font>  valuable  rights to our <font color="blue">potential products</font> or <font color="blue">proprietary</font>     <font color="blue">technologies</font>, or <font color="blue">grant licenses on terms</font> that are not favorable to us</td>
    </tr>
    <tr>
      <td>For     example, we might be forced to <font color="blue">relinquish</font> all or a portion of our sales and     <font color="blue">marketing rights <font color="blue">with respect</font></font> to Proellex, Androxal or other potential     products or <font color="blue">license <font color="blue">intellectual property</font></font> that <font color="blue">enables licensees</font> to develop     <font color="blue">competing products</font></td>
    </tr>
    <tr>
      <td>We licensed our rights to Proellex from the National Institutes of Health,     or NIH, and our inability to fulfill our <font color="blue">commitments</font> and <font color="blue">obligations</font> under     <font color="blue">such license may</font> result in <font color="blue">forfeiture</font> of our rights</td>
    </tr>
    <tr>
      <td>Our rights to Proellex are <font color="blue">licensed exclusively</font> to us from the NIH     under a <font color="blue">license <font color="blue">agreement</font></font></td>
    </tr>
    <tr>
      <td>This <font color="blue">license <font color="blue">agreement</font></font> contains numerous detailed     performance <font color="blue">obligations</font>, with time <font color="blue">sensitive dates</font> for compliance, relating     to clinical <font color="blue">development</font> and <font color="blue">commercialization</font> <font color="blue">activities</font> required by us or     our  designated third-party providers, as well as <font color="blue">additional</font> financial     <font color="blue">milestones</font> and royalties</td>
    </tr>
    <tr>
      <td>Failure to achieve the <font color="blue">benchmarks</font> specified in the     commercial  <font color="blue">development</font> plan attached to the <font color="blue">license <font color="blue">agreement</font></font> or meet     payment <font color="blue">obligations</font> could result in <font color="blue">termination</font> of the <font color="blue">license <font color="blue">agreement</font></font> and     the loss of our rights to develop and <font color="blue">commercialize</font> Proellex</td>
    </tr>
    <tr>
      <td>During the     period when we were considering <font color="blue">redeployment</font> of our assets, we were not in     compliance with all of the <font color="blue">original <font color="blue">requirements</font></font> stated in the commercial     <font color="blue">development</font> plan</td>
    </tr>
    <tr>
      <td>In July 2002, the <font color="blue">license <font color="blue">agreement</font></font> was amended to include     a revision of the original commercial <font color="blue">development</font> plan relating to the     <font color="blue">targeted dates</font> for <font color="blue">certain objectives</font></td>
    </tr>
    <tr>
      <td><font color="blue">Additional </font>updates of the original     commercial <font color="blue">development</font> plan have <font color="blue">been reached with</font> the NIH <font color="blue">thereafter as</font>     <font color="blue">development</font> plans have evolved</td>
    </tr>
    <tr>
      <td>There can be no assurance that we will be     able to meet any or all of <font color="blue">such performance objectives</font> in the future on a     <font color="blue">timely basis</font> or at all, or that, if we fail to meet any of such objectives,     the NIH <font color="blue">will again agree</font> to <font color="blue">such revised objectives</font></td>
    </tr>
    <tr>
      <td>The NIH has the ability     to terminate the <font color="blue">agreement</font> for failure to <font color="blue">comply with</font> the material terms     contained in the <font color="blue">license <font color="blue">agreement</font></font> and for other <font color="blue">reasons as outlined</font> in the     <font color="blue">agreement</font></td>
    </tr>
    <tr>
      <td><font color="blue">Should the NIH </font>terminate the <font color="blue">license <font color="blue">agreement</font></font>, we would lose all     rights to <font color="blue">commercialize</font> Proellex, <font color="blue">which would</font> have a material adverse effect     on us</td>
    </tr>
    <tr>
      <td>There is a <font color="blue">patent holder</font> that claims <font color="blue">priority over</font> our <font color="blue">patent <font color="blue">application</font></font>     for Androxal</td>
    </tr>
    <tr>
      <td>A  third  party  holds  an <font color="blue">issued patent</font> related to the use of an     anti-estrogen  such  <font color="blue">as clomiphene citrate</font> for use in the treatment of     androgen <font color="blue">deficiency</font> and disorders related thereto</td>
    </tr>
    <tr>
      <td>In our <font color="blue">prior filings with</font>     the SEC, we have described our request to the US Patent and Trademark     Office, or PTO, for re-examination of this third party’s patent based on     several printed <font color="blue">publications</font> <font color="blue">previously</font> available in the <font color="blue">public domain</font></td>
    </tr>
    <tr>
      <td>The     <font color="blue">third party amended</font> the claims in the <font color="blue">reexamination</font> <font color="blue">proceedings</font>, which has     led the PTO to determine that the amended claims are patentable in view of     the <font color="blue">publications</font> under <font color="blue">consideration</font></td>
    </tr>
    <tr>
      <td>We believe that the amended claims are     invalid based on, among other things, <font color="blue">additional</font> prior <font color="blue">publications</font> not yet     considered by the PTO We intend to seek further <font color="blue">reexamination</font> of the third     party’s patent in light of a number of these <font color="blue">publications</font></td>
    </tr>
    <tr>
      <td>There is no     assurance that the <font color="blue">patent ultimately will</font> be reversed</td>
    </tr>
    <tr>
      <td>If <font color="blue">such patent</font> is not     cancelled, we may then be required to obtain a <font color="blue">license from</font> the holder of     <font color="blue">such patent</font> in order to develop Androxal further, and <font color="blue">such license may</font> not     be <font color="blue">available on</font> acceptable terms or at all</td>
    </tr>
    <tr>
      <td>In this case, we may not be able     to develop or <font color="blue">commercialize</font> Androxal</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> that our <font color="blue">manufacture</font>, use or sale of our <font color="blue">product <font color="blue">candidates</font></font>     will not <font color="blue">infringe on</font> the <font color="blue">patent rights</font> of others</td>
    </tr>
    <tr>
      <td>There can be no assurance that the <font color="blue">manufacture</font>, use or sale of any of     our <font color="blue">product <font color="blue">candidates</font></font> will not infringe the <font color="blue">patent rights</font> of others</td>
    </tr>
    <tr>
      <td>We may     be unable to <font color="blue">avoid <font color="blue">infringement</font></font> of the <font color="blue">patent rights</font> of others and may be     required to seek a license, defend an <font color="blue"><font color="blue">infringement</font> action</font> or challenge the     validity of the patents in court</td>
    </tr>
    <tr>
      <td>There can be no assurance that a license     to the allegedly infringed                                        -14-       _________________________________________________________________    [62]Table of <font color="blue">Contents       </font><font color="blue">patents will</font> be available to us on terms and <font color="blue">conditions</font> acceptable to us, if     at all, or that we <font color="blue">will prevail</font> in any <font color="blue">patent <font color="blue">litigation</font></font></td>
    </tr>
    <tr>
      <td>Patent <font color="blue">litigation</font>     is <font color="blue">extremely costly</font> and time-consuming, and there can be no assurance that     we will have <font color="blue">sufficient resources</font> to defend any possible <font color="blue">litigation</font> related     to <font color="blue">such <font color="blue">infringement</font></font></td>
    </tr>
    <tr>
      <td>If we do not obtain a <font color="blue">license on</font> acceptable terms     under <font color="blue">such patent</font>s, or are <font color="blue">found liable</font> for <font color="blue">infringement</font>, or are not able to     have <font color="blue">such patent</font>s declared invalid, we may be liable for <font color="blue">significant</font> money     damages, may encounter <font color="blue">significant</font> delays in bringing our <font color="blue">product <font color="blue">candidates</font></font>     to market, or may be <font color="blue">precluded from participating</font> in the <font color="blue">manufacture</font>, use or     sale of any such <font color="blue">product <font color="blue">candidates</font></font>, any of <font color="blue">which would</font> materially and     <font color="blue">adversely affect</font> our business</td>
    </tr>
    <tr>
      <td>We face substantial <font color="blue">uncertainty</font> in our ability to protect our patents and     <font color="blue">proprietary</font> <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>Our ability to <font color="blue">commercialize</font> our <font color="blue">products will depend</font>, in part, on our     or our <font color="blue">licensors</font>’ ability to obtain patents, to enforce those patents and     <font color="blue">preserve <font color="blue"><font color="blue">trade secret</font>s</font></font>, and to operate <font color="blue">without infringing on</font> the <font color="blue">proprietary</font>     rights of others</td>
    </tr>
    <tr>
      <td>The <font color="blue">patent positions</font> of <font color="blue">bio<font color="blue">pharmaceutical</font> companies</font> are     <font color="blue">highly uncertain</font> and <font color="blue">involve complex legal</font> and factual questions</td>
    </tr>
    <tr>
      <td>There can     be no assurance that:       •   <font color="blue">patent <font color="blue">application</font></font>s for our product Androxal will result in issued     patents;         •   <font color="blue">patent protection will</font> be secured for any <font color="blue">particular <font color="blue">technology</font></font>;         •   any patents that have been or may be issued to us, such as our pending     <font color="blue">patent <font color="blue">application</font></font> for Androxal, or our <font color="blue">licensors</font>, such as the patent(s) and     <font color="blue">application</font>(s) underlying our Proellex compound, when issued, will be valid     or enforceable;         •   any <font color="blue">patents will</font> provide meaningful protection to us;         •   <font color="blue">others will</font> not be able to <font color="blue">design around</font> the patents; or         •   our <font color="blue">patents will</font> provide a <font color="blue"><font color="blue">competitive</font> advantage</font> or have commercial     <font color="blue">application</font></td>
    </tr>
    <tr>
      <td>The failure to obtain and maintain <font color="blue">adequate patent protection would</font>     have a material adverse effect on us and may <font color="blue">adversely affect</font> our ability to     <font color="blue">enter into</font>, or affect the terms of, any <font color="blue">arrangement</font> for the marketing of any     product</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> that our <font color="blue">patents will</font> not be <font color="blue">challenged by others</font></td>
    </tr>
    <tr>
      <td>We  <font color="blue">could incur</font> substantial costs in     <font color="blue">proceedings</font>,  including  <font color="blue">interference</font>  <font color="blue">proceedings</font>  before the PTO and     comparable  <font color="blue">proceedings</font>  before similar agencies in other countries in     <font color="blue">connection with</font> any claims that may arise in the future</td>
    </tr>
    <tr>
      <td>These <font color="blue">proceedings</font>     could result in <font color="blue">adverse <font color="blue">decisions about</font></font> the <font color="blue">patentability</font> of our or our     <font color="blue">licensors</font>’ <font color="blue">inventions</font> and products, as well as about the <font color="blue">enforceability</font>,     validity  or  scope of <font color="blue">protection afforded by</font> the patents</td>
    </tr>
    <tr>
      <td>Any adverse     <font color="blue">decisions about</font> the <font color="blue">patentability</font> of our <font color="blue">product <font color="blue">candidates</font></font> could cause us     to <font color="blue">either lose rights</font> to develop and <font color="blue">commercialize</font> our <font color="blue">product <font color="blue">candidates</font></font> or     to <font color="blue">license such rights at</font> substantial cost to us</td>
    </tr>
    <tr>
      <td>In addition, even if we     were successful in such <font color="blue">proceedings</font>, the cost and delay of such <font color="blue">proceedings</font>     <font color="blue">would most likely</font> have a material adverse effect on our business</td>
    </tr>
    <tr>
      <td><font color="blue">Confidentiality </font><font color="blue">agreement</font>s with employees and others may not <font color="blue">adequately</font>     <font color="blue">prevent disclosure</font> of <font color="blue"><font color="blue">trade secret</font>s</font> and other <font color="blue">proprietary</font> information, may     not <font color="blue">adequately</font> protect our <font color="blue">intellectual property</font>, and will not <font color="blue">prevent third</font>     parties  from  <font color="blue">independently</font>  <font color="blue">discovering</font>  <font color="blue">technology</font> similar to or in     <font color="blue"><font color="blue">competition</font> with</font> our <font color="blue">intellectual property</font></td>
    </tr>
    <tr>
      <td>We rely on <font color="blue"><font color="blue">trade secret</font>s</font> and other unpatented <font color="blue">proprietary</font> information     in  our product <font color="blue">development</font> <font color="blue">activities</font></td>
    </tr>
    <tr>
      <td>To the extent we rely on trade     secrets and unpatented know-how to maintain our <font color="blue">competitive</font> <font color="blue">technological</font>     position,  there can be no assurance that others may not <font color="blue">independently</font>     develop the same or similar <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>We seek to protect <font color="blue"><font color="blue">trade secret</font>s</font>     and <font color="blue">proprietary</font> knowledge, in part, through <font color="blue">confidential</font>ity <font color="blue">agreement</font>s with     our  employees,  consultants, advisors, <font color="blue">collaborators</font> and <font color="blue">contractors</font></td>
    </tr>
    <tr>
      <td>Nevertheless, these <font color="blue">agreement</font>s may not <font color="blue">effective</font>ly <font color="blue">prevent disclosure</font> of our     <font color="blue">confidential</font> information and may not <font color="blue">provide us with</font> an <font color="blue">adequate remedy</font> in     the event of <font color="blue">unauthorized disclosure</font> of such information</td>
    </tr>
    <tr>
      <td>If our employees,     scientific consultants, advisors, <font color="blue">collaborators</font> or <font color="blue">contractors</font> develop     <font color="blue">inventions</font>  or  processes  <font color="blue">independently</font> that may be applicable to our     <font color="blue">technologies</font>, <font color="blue">product <font color="blue">candidates</font></font> or products, disputes may arise about     ownership of <font color="blue">proprietary</font> rights to those <font color="blue">inventions</font> and processes</td>
    </tr>
    <tr>
      <td><font color="blue">Such     </font><font color="blue">inventions</font> and <font color="blue">processes will</font> not <font color="blue">necessarily</font> become our property, but may     remain the property of those persons or their employers</td>
    </tr>
    <tr>
      <td><font color="blue">Protracted </font>and     costly <font color="blue">litigation</font> could be <font color="blue">necessary</font> to enforce and determine the scope of     our  <font color="blue">proprietary</font> rights</td>
    </tr>
    <tr>
      <td>If we fail to obtain or maintain <font color="blue">trade secret</font>     protection for any reason, the <font color="blue">competition</font> we face could increase, reducing     our <font color="blue">potential revenues</font> and <font color="blue">adversely affect</font>ing our ability to attain or     maintain <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>Delays in the <font color="blue">commencement</font> of <font color="blue">clinical testing</font> of our current and potential     <font color="blue">product <font color="blue">candidates</font></font> could result in <font color="blue">increased costs</font> to us and delay our     ability to <font color="blue">generate revenues</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">product <font color="blue">candidates</font></font> will require continued pre<font color="blue">clinical testing</font> and     extensive  clinical  trials  prior  to  the submission of a <font color="blue">regulatory</font>     <font color="blue">application</font>  for <font color="blue">commercial sale</font>s</td>
    </tr>
    <tr>
      <td>We <font color="blue">recently commenced</font> our <font color="blue">Phase III </font>    <font color="blue">clinical trial</font> f<font color="blue">or Androxal </font>in the <font color="blue">United States </font>for                                        -15-       _________________________________________________________________    [63]Table of <font color="blue">Contents       </font>the treatment of <font color="blue">men with <font color="blue">testosterone</font></font> <font color="blue">deficiency</font> and our <font color="blue">Phase II </font>clinical     trial  for Proellex in the <font color="blue">United States </font>for the treatment of symptoms     associated with <font color="blue">uterine fibroids</font></td>
    </tr>
    <tr>
      <td>We also <font color="blue">recently commenced</font> a <font color="blue">Phase II </font>    clinical  trial  in  Europe  for the treatment of <font color="blue">women suffering from</font>     <font color="blue">endometriosis</font></td>
    </tr>
    <tr>
      <td>We have limited experience conducting <font color="blue"><font color="blue">clinical trial</font>s</font> for     these <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>In part, because of this limited experience, we do     not know <font color="blue">whether future</font> planned <font color="blue"><font color="blue">clinical trial</font>s</font> will begin on time, if at     all</td>
    </tr>
    <tr>
      <td>Delays in the <font color="blue">commencement</font> of <font color="blue">clinical testing</font> could <font color="blue">significant</font>ly     increase   our   product  <font color="blue">development</font>  costs  and  delay  any  product     <font color="blue">commercialization</font></td>
    </tr>
    <tr>
      <td>In addition, many of the factors that may cause, or lead     to, a delay in the <font color="blue">commencement</font> of <font color="blue"><font color="blue">clinical trial</font>s</font> <font color="blue">may also ultimately lead</font>     to denial of <font color="blue">regulatory</font> approval of a <font color="blue">product candidate</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">commencement</font> of <font color="blue"><font color="blue">clinical trial</font>s</font> can be delayed for a variety of     reasons, including delays in:       •   conducting and completing a two-year rat <font color="blue">carcinogenicity</font> study     required by the FDA prior to submission of an NDA f<font color="blue">or Androxal </font>and Proellex;         •   <font color="blue">demonstrating sufficient safety</font> and efficacy in past <font color="blue"><font color="blue">clinical trial</font>s</font>     to obtain <font color="blue">regulatory</font> approval to commence a further <font color="blue">clinical trial</font>;         •   reaching <font color="blue">agreement</font> on acceptable <font color="blue">terms with prospective contract</font>     <font color="blue"><font color="blue">manufacture</font>rs</font>  for  <font color="blue">manufacturing</font>  sufficient  quantities of a product     candidate; and         •   obtaining <font color="blue">institutional review board approval</font> to conduct a clinical     trial at a <font color="blue">prospective site</font></td>
    </tr>
    <tr>
      <td>In addition, the <font color="blue">commencement</font> of <font color="blue"><font color="blue">clinical trial</font>s</font> may be <font color="blue">delayed due</font> to     insufficient  patient enrollment, which is a function of many factors,     including the size of the <font color="blue">patient population</font>, the nature of the protocol,     the proximity of patients to <font color="blue">clinical sites</font>, the <font color="blue">availability</font> of <font color="blue">effective</font>     <font color="blue">treatments</font> for the <font color="blue">relevant disease</font>, and the <font color="blue">eligibility criteria</font> for the     <font color="blue">clinical trial</font></td>
    </tr>
    <tr>
      <td>Delays in the <font color="blue">completion</font> of, or the <font color="blue">termination</font> of, <font color="blue">clinical testing</font> of our     current and potential <font color="blue">product <font color="blue">candidates</font></font> could result in <font color="blue">increased costs</font> to     us, and <font color="blue">could delay</font> or <font color="blue"><font color="blue">prevent us from</font> generating revenues</font></td>
    </tr>
    <tr>
      <td>Once  a <font color="blue">clinical trial</font> has begun, it may be delayed, suspended or     terminated by us or the FDA, or other <font color="blue">regulatory</font> authorities due to a number     of factors, including:       •   <font color="blue">ongoing discussions with</font> the FDA or other <font color="blue">regulatory</font> authorities     regarding the scope or design of our <font color="blue"><font color="blue">clinical trial</font>s</font>;         •   the FDA may not <font color="blue">accept data</font> obtained <font color="blue">from clinical studies conducted</font>     in Europe or other non-<font color="blue">United States </font><font color="blue">jurisdictions as meeting</font> all applicable     FDA <font color="blue">clinical trial</font> standards;         •   lower than anticipated <font color="blue">retention rate</font> of patients in <font color="blue"><font color="blue">clinical trial</font>s</font>;         •   inspection of the <font color="blue">clinical trial</font> <font color="blue">operations</font> or <font color="blue">trial sites by</font> the FDA     or other <font color="blue">regulatory</font> authorities resulting in the imposition of a clinical     hold;         •   lack of <font color="blue">adequate funding</font> to continue <font color="blue"><font color="blue">clinical trial</font>s</font>;         •   in<font color="blue">sufficient supply</font> or deficient quality of drug <font color="blue">candidates</font> or other     materials <font color="blue">necessary</font> for the conduct of our <font color="blue"><font color="blue">clinical trial</font>s</font>; or         •   <font color="blue">serious adverse events</font> or other undesirable drug-related side effects     experienced <font color="blue">by participants</font></td>
    </tr>
    <tr>
      <td>Many  of  these  factors  that may lead to a delay, suspension or     <font color="blue">termination</font> of <font color="blue">clinical testing</font> of a current or potential <font color="blue">product candidate</font>     <font color="blue">may also ultimately lead</font> to denial of <font color="blue">regulatory</font> approval of a current or     potential <font color="blue">product candidate</font></td>
    </tr>
    <tr>
      <td>We experienced a clinical hold beginning in 1999 during our <font color="blue">development</font>     of VASOMAX, which has resulted in our delaying <font color="blue">development</font> of that product     candidate</td>
    </tr>
    <tr>
      <td>We have not <font color="blue">yet been able</font> to have the <font color="blue">partial clinical</font> hold     removed</td>
    </tr>
    <tr>
      <td>In  addition, while VASOMAX was <font color="blue">previously</font> approved in eight     countries in Latin America, <font color="blue">such approval</font> is not current</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font>     that we will be able to (i) have the <font color="blue">partial clinical</font> hold <font color="blue">removed by</font> the     FDA   in   the  United  States,  (ii) develop  VASOMAX  or  our  other     <font color="blue">phentolamine</font>-based products to a point where they are <font color="blue">attractive acquisition</font>     <font color="blue">candidates</font> by <font color="blue">third parties</font> or (iii) re-establish approval status in any of     the Latin American countries in which we were <font color="blue">previously</font> approved</td>
    </tr>
    <tr>
      <td>If  we experience delays in the <font color="blue">completion</font> of, or <font color="blue">termination</font> of,     <font color="blue">clinical testing</font> of any <font color="blue">product <font color="blue">candidates</font></font> in the future, our financial     results and the <font color="blue">commercial prospects</font> for our <font color="blue">product <font color="blue">candidates</font></font> will be     harmed, and our ability to <font color="blue">generate product revenues will</font> be delayed</td>
    </tr>
    <tr>
      <td>-16-       _________________________________________________________________    [64]Table of <font color="blue">Contents       </font>Even if we <font color="blue">successfully</font> complete <font color="blue"><font color="blue">clinical trial</font>s</font> for <font color="blue">Proellex and Androxal</font>,     there  are <font color="blue">no assurances</font> that we will be able to submit, or obtain FDA     approval of, a <font color="blue">new drug <font color="blue">application</font></font></td>
    </tr>
    <tr>
      <td>There can be no assurance that, if our <font color="blue"><font color="blue">clinical trial</font>s</font> for Proellex and     Androxal are <font color="blue">successfully</font> completed, we will be able to submit a new drug     <font color="blue">application</font>, or NDA, to the FDA or that any NDA we <font color="blue">submit will</font> be approved     by the FDA in a <font color="blue">timely manner</font>, if at all</td>
    </tr>
    <tr>
      <td>After completing <font color="blue"><font color="blue">clinical trial</font>s</font>     for a <font color="blue">product candidate</font> in humans, a drug dossier is prepared and submitted     to the FDA as an NDA, and includes all preclinical and <font color="blue">clinical trial</font> data     that clearly establish both short-term and long-term safety, as well as     <font color="blue">carcinogenicity</font> studies for a <font color="blue">product candidate</font> that will be used as a     <font color="blue">chronic treatment</font>, and data that <font color="blue">establishes</font> the statistically <font color="blue">significant</font>     efficacy of a <font color="blue">product candidate</font>, in order to allow the FDA to review such     drug  dossier  and  to  consider  a <font color="blue">product candidate</font> for approval for     <font color="blue">commercialization</font> <font color="blue">in the United States</font></td>
    </tr>
    <tr>
      <td>If we are unable to submit an NDA     with  respect  to <font color="blue">Proellex or Androxal</font>, or if any NDA we submit is not     <font color="blue">approved by</font> the FDA, we will be unable to <font color="blue">commercialize</font> that product</td>
    </tr>
    <tr>
      <td>The     FDA can and does reject NDAs and requires <font color="blue">additional</font> <font color="blue"><font color="blue">clinical trial</font>s</font>, even     when  drug  <font color="blue">candidates</font>  perform  well  or achieve favorable results in     large-scale <font color="blue">Phase III </font><font color="blue"><font color="blue">clinical trial</font>s</font></td>
    </tr>
    <tr>
      <td>If we fail to <font color="blue">commercialize</font> <font color="blue">Proellex     </font>or Androxal, we may be unable to generate <font color="blue">sufficient revenues</font> to continue     <font color="blue">operations</font> or <font color="blue">attain <font color="blue">profitability</font></font> and our reputation in the industry and in     the <font color="blue">investment community would likely</font> be damaged</td>
    </tr>
    <tr>
      <td>If <font color="blue">commercialize</font>d, our <font color="blue">product <font color="blue">candidates</font></font> may not be approved for sufficient     <font color="blue"><font color="blue">government</font>al</font> or third-party <font color="blue">reimbursement</font>s, <font color="blue">which would</font> <font color="blue">adversely affect</font> our     ability to market our <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>In the <font color="blue">United States </font>and elsewhere, sales of <font color="blue">pharmaceutical</font> products     depend in <font color="blue">significant</font> part on the <font color="blue">availability</font> of <font color="blue">reimbursement</font> to the     consumer from third-party payers, such as <font color="blue">government</font> and <font color="blue">private insurance</font>     plans</td>
    </tr>
    <tr>
      <td>Since we have <font color="blue">no <font color="blue">commercial products</font></font>, we have not had to face this     issue yet; however, third-party payers are <font color="blue">increasingly challenging</font> the     <font color="blue">prices charged</font> for <font color="blue">medical products</font> and services</td>
    </tr>
    <tr>
      <td>It will be time consuming     and expensive for us to go through the process of seeking <font color="blue">reimbursement</font> from     Medicaid,  Medicare  and private payers for <font color="blue">Proellex and Androxal</font></td>
    </tr>
    <tr>
      <td>Our     products  may  not  be  considered  cost  <font color="blue">effective</font>,  and coverage and     <font color="blue">reimbursement</font> may not be available or sufficient to allow us to sell our     <font color="blue">products on</font> a <font color="blue">competitive</font> and <font color="blue">profitable basis</font></td>
    </tr>
    <tr>
      <td>The passage of the Medicare     Prescription Drug and Modernization Act of 2003 imposes new <font color="blue">requirements</font> for     the <font color="blue">distribution</font> and pricing of <font color="blue">prescription</font> drugs which may <font color="blue">negatively</font>     affect the marketing of our <font color="blue">potential products</font></td>
    </tr>
    <tr>
      <td>If we <font color="blue">successfully</font> develop products but those products do not achieve and     maintain <font color="blue">market <font color="blue">acceptance</font></font>, our business will not be profitable</td>
    </tr>
    <tr>
      <td>Even if our <font color="blue">product <font color="blue">candidates</font></font> are approved for <font color="blue">commercial sale</font> by the     FDA or other <font color="blue">regulatory</font> authorities, the degree of <font color="blue">market <font color="blue">acceptance</font></font> of any     approved product by physicians, healthcare professionals and third-party     payers and our <font color="blue">profitability</font> and <font color="blue">growth will depend on</font> a number of factors,     including:       •   <font color="blue">relative convenience</font> and ease of <font color="blue">administration</font>;         •   the prevalence and severity of any adverse side effects;         •   <font color="blue">availability</font>, <font color="blue">effective</font>ness and cost of alternative <font color="blue">treatments</font>;         •   pricing and cost <font color="blue">effective</font>ness of our drugs;         •   <font color="blue">effective</font>ness of our or our <font color="blue">collaborators</font>’ sales and marketing     strategies; and         •   our ability to obtain sufficient third-party <font color="blue">insurance coverage</font> or     <font color="blue">reimbursement</font></td>
    </tr>
    <tr>
      <td>If  Proellex  does  not  provide a <font color="blue"><font color="blue">treatment regime</font>n</font> that is more     beneficial than Lupron, a GnRH agonist and the <font color="blue">current therapeutic</font> standard     of care for <font color="blue">uterine fibroids</font>, or <font color="blue">otherwise <font color="blue">provide patient benefit</font></font>, it     <font color="blue">likely will</font> not be <font color="blue">accepted <font color="blue">favorably by</font></font> the market</td>
    </tr>
    <tr>
      <td>Similarly, if <font color="blue">Androxal     </font>does not provide a <font color="blue">treatment regime</font> that is more beneficial than Androgel,     the current standard of care for the treatment of <font color="blue">testosterone</font> <font color="blue">deficiency</font>,     or  otherwise  <font color="blue">provide patient benefit</font>, it <font color="blue">likely will</font> not be accepted     <font color="blue">favorably by</font> the market</td>
    </tr>
    <tr>
      <td>And if VASOMAX, Bimexes or ERxin do not provide a     <font color="blue">treatment regime</font> more beneficial than Viagra, Cialis or other <font color="blue">drugs already</font>     on  the  market for <font color="blue">male erectile dysfunction</font>, they <font color="blue">will likely</font> not be     <font color="blue">accepted <font color="blue">favorably by</font></font> the market</td>
    </tr>
    <tr>
      <td>If any products we may develop do not     achieve <font color="blue">market <font color="blue">acceptance</font></font>, then we will not <font color="blue">generate sufficient</font> revenue to     achieve or maintain <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>In addition, even if our products achieve <font color="blue">market <font color="blue">acceptance</font></font>, we may not     be able to maintain that <font color="blue">market <font color="blue">acceptance</font></font> over time if:       •   <font color="blue">new products</font> or <font color="blue">technologies</font> are introduced that are more favorably     received than our products, are more cost <font color="blue">effective</font> or render our products     obsolete;         •   <font color="blue">unforeseen <font color="blue">complications</font></font> arise <font color="blue">with respect</font> to use of our products; or                                        -17-       _________________________________________________________________    [65]Table of <font color="blue">Contents       </font>  •   sufficient third-party <font color="blue">insurance coverage</font> or <font color="blue">reimbursement</font> does not     <font color="blue">remain available</font></td>
    </tr>
    <tr>
      <td>We currently rely on third-party <font color="blue"><font color="blue">manufacture</font>rs</font> and other <font color="blue">third parties</font> for     production  of  our  product  <font color="blue">candidates</font>,  and our <font color="blue">dependence on</font> these     <font color="blue"><font color="blue">manufacture</font>rs</font> may impair the <font color="blue">development</font> of our <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>Currently, we do not have the <font color="blue">ability internally</font> to <font color="blue">manufacture</font> the     <font color="blue">product <font color="blue">candidates</font></font> that we need to conduct our <font color="blue"><font color="blue">clinical trial</font>s</font></td>
    </tr>
    <tr>
      <td>We have     entered into purchase orders with third-party <font color="blue"><font color="blue">manufacture</font>rs</font> to produce our     supplies of <font color="blue">Proellex and Androxal</font>; however, we have no long-term contracts     <font color="blue">with suppliers</font> of either <font color="blue">product candidate</font></td>
    </tr>
    <tr>
      <td>To date, other than some initial     <font color="blue">amounts from</font> the NIH, we have obtained all of our supply of Proellex for our     <font color="blue"><font color="blue">clinical trial</font>s</font> from <font color="blue">Bridge Organics </font>pursuant to <font color="blue">purchase orders on</font> an as     needed basis</td>
    </tr>
    <tr>
      <td>We are in the process of identifying a <font color="blue">manufacture</font>r for a     long-term  supply  contract  of  Proellex</td>
    </tr>
    <tr>
      <td>There are <font color="blue">several potential</font>     <font color="blue"><font color="blue">manufacture</font>rs</font> capable of <font color="blue">manufacturing</font> Proellex</td>
    </tr>
    <tr>
      <td>However, there can be no     assurance  that  we will be able to <font color="blue">successfully</font> negotiate a long-term     <font color="blue">agreement</font> with any of such potential <font color="blue"><font color="blue">manufacture</font>rs</font> at a <font color="blue">reasonable price</font> and     on other acceptable terms or that any potential <font color="blue">manufacture</font>r will be able to     reproduce the results obtained by <font color="blue">Bridge Organics </font>in <font color="blue">manufacturing</font> <font color="blue">Proellex     </font>to date</td>
    </tr>
    <tr>
      <td>We have not faced any material <font color="blue">problems with</font> <font color="blue">BioVectra </font>in supplying us with     our <font color="blue">necessary</font> quantities <font color="blue">of Androxal </font>for our <font color="blue"><font color="blue">clinical trial</font>s</font> and anticipate     utilizing them for commercial production if Androxal is approved</td>
    </tr>
    <tr>
      <td>There are     numerous other suitable <font color="blue"><font color="blue">manufacture</font>rs</font> capable of <font color="blue">manufacturing</font> Androxal</td>
    </tr>
    <tr>
      <td>For  the  foreseeable  future,  we  expect to continue to rely on     third-party <font color="blue"><font color="blue">manufacture</font>rs</font> and other <font color="blue">third parties</font> to produce, package and     <font color="blue">store <font color="blue">sufficient quantities</font></font> of Proellex, Androxal and any <font color="blue">future product</font>     <font color="blue">candidates</font> for use in our <font color="blue"><font color="blue">clinical trial</font>s</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">product <font color="blue">candidates</font></font> are     complicated and expensive to <font color="blue">manufacture</font></td>
    </tr>
    <tr>
      <td>If our third-party <font color="blue"><font color="blue">manufacture</font>rs</font>     fail to deliver our <font color="blue">product <font color="blue">candidates</font></font> for <font color="blue">clinical use on</font> a <font color="blue">timely basis</font>,     <font color="blue">with sufficient quality</font>, and at commercially <font color="blue">reasonable price</font>s, we may be     required  to delay or suspend <font color="blue"><font color="blue">clinical trial</font>s</font> or <font color="blue">otherwise discontinue</font>     <font color="blue">development</font> and production of our <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>While we may be able     to  identify  <font color="blue">replacement</font> third-party <font color="blue"><font color="blue">manufacture</font>rs</font> or develop our own     <font color="blue">manufacturing</font> <font color="blue">capabilities</font> for these <font color="blue">product <font color="blue">candidates</font></font>, this <font color="blue">process would</font>     likely cause a delay in the <font color="blue">availability</font> of our <font color="blue">product <font color="blue">candidates</font></font> and an     increase  in  costs</td>
    </tr>
    <tr>
      <td>We  may also be required to <font color="blue">enter into</font> long-term     <font color="blue">manufacturing</font>  <font color="blue">agreement</font>s  that  contain exclusivity provisions and/or     substantial <font color="blue">termination</font> penalties</td>
    </tr>
    <tr>
      <td>In addition, third-party <font color="blue"><font color="blue">manufacture</font>rs</font>     may have a limited number of <font color="blue">facilities</font> in which our <font color="blue">product <font color="blue">candidates</font></font> can     be produced, and any <font color="blue">interruption</font> of the operation of those <font color="blue">facilities</font> due     to <font color="blue">events such as equipment malfunction</font> or failure or damage to the <font color="blue">facility</font>     <font color="blue">by natural disasters could</font> result in the <font color="blue">cancellation</font> of shipments, loss of     product in the <font color="blue">manufacturing</font> process or a shortfall in <font color="blue">available product</font>     <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>We  also  depend  <font color="blue">on outside vendors</font> for the supply of the active     <font color="blue">pharmaceutical</font> ingredients and <font color="blue">raw materials used</font> to produce our product     <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>Although we believe there are numerous third-party suppliers     available, if our current third-party suppliers were to <font color="blue">cease production</font> or     <font color="blue">otherwise fail</font> to <font color="blue">supply us with quality raw materials</font> and we were unable to     contract  on acceptable terms for these <font color="blue">raw materials with alternative</font>     suppliers, our ability to have our <font color="blue">product <font color="blue">candidates</font></font> <font color="blue">manufacture</font>d and to     conduct pre<font color="blue">clinical testing</font> and <font color="blue"><font color="blue">clinical trial</font>s</font> of our <font color="blue">product <font color="blue">candidates</font></font>     would be <font color="blue">adversely affect</font>ed</td>
    </tr>
    <tr>
      <td>Our <font color="blue">product <font color="blue">candidates</font></font> have only been <font color="blue">manufacture</font>d in small quantities to     date, and we <font color="blue">may face delays</font> or <font color="blue">complications</font> in <font color="blue">manufacturing</font> quantities of     our <font color="blue">product <font color="blue">candidates</font></font> in <font color="blue">sufficient quantities</font> to meet the demands of late     stage <font color="blue"><font color="blue">clinical trial</font>s</font> and marketing</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> that we will be able to <font color="blue">successfully</font> increase the     <font color="blue">manufacturing</font> capacity or scale-up <font color="blue">manufacturing</font> volume per batch, whether     on our own or in reliance on third-party <font color="blue"><font color="blue">manufacture</font>rs</font>, for any of our     <font color="blue">product <font color="blue">candidates</font></font> in a timely or <font color="blue">economical manner</font>, or at all</td>
    </tr>
    <tr>
      <td>To date our     non-<font color="blue">phentolamine</font>-based <font color="blue">product <font color="blue">candidates</font></font> have been <font color="blue">manufacture</font>d exclusively     by <font color="blue">third parties</font> in small quantities for pre-clinical and <font color="blue"><font color="blue">clinical trial</font>s</font></td>
    </tr>
    <tr>
      <td>We  will  need  to  arrange for the production of <font color="blue">significant</font>ly larger     quantities of such <font color="blue">product <font color="blue">candidates</font></font> for future <font color="blue"><font color="blue">clinical trial</font>s</font> and for     future <font color="blue">commercial sale</font> in the event that our <font color="blue">product <font color="blue">candidates</font></font> are approved     by  the  FDA  or  foreign  <font color="blue">regulatory</font>  bodies</td>
    </tr>
    <tr>
      <td><font color="blue">Significant </font>scale-up of     <font color="blue">manufacturing</font> may require certain <font color="blue">additional</font> validation studies, which the     FDA must review and approve</td>
    </tr>
    <tr>
      <td>If we or our third-party <font color="blue"><font color="blue">manufacture</font>rs</font> are     unable to <font color="blue">successfully</font> increase the <font color="blue">manufacturing</font> capacity for a product     candidate, the <font color="blue">regulatory</font> approval or <font color="blue">commercial launch</font> of that product     candidate  may be delayed or there may be a shortage in supply of that     <font color="blue">product candidate</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">product <font color="blue">candidates</font></font> require precise, high-quality <font color="blue">manufacturing</font> which may     not be <font color="blue">available at</font> acceptable costs</td>
    </tr>
    <tr>
      <td><font color="blue">Proellex and Androxal</font> are <font color="blue">novel compounds</font> that have never been produced     in  large  scale</td>
    </tr>
    <tr>
      <td>As in the <font color="blue">development</font> of any new compound, there are     <font color="blue">underlying risks associated with</font> its <font color="blue">manufacture</font></td>
    </tr>
    <tr>
      <td>These risks include, but     are  not  limited to, cost, process scale-up, process reproducibility,     <font color="blue">construction</font>  of  a suitable process plant, timely <font color="blue">availability</font> of raw     materials, as well as <font color="blue">regulatory</font> issues associated with the <font color="blue">manufacture</font> of     an active <font color="blue">pharmaceutical</font> agent</td>
    </tr>
    <tr>
      <td>Any of these risks may <font color="blue">prevent us from</font>     <font color="blue">successfully</font> developing <font color="blue">Proellex or Androxal</font></td>
    </tr>
    <tr>
      <td>Our failure, or the failure of     our  third-party  <font color="blue"><font color="blue">manufacture</font>rs</font>  to  achieve  and  maintain these high     <font color="blue">manufacturing</font> standards, including the incidence of <font color="blue">manufacturing</font> errors and     <font color="blue">reliable product packaging</font> for diverse environmental <font color="blue">conditions</font>, could     result in <font color="blue">patient injury</font> or death, product recalls or withdrawals, delays or     failures in <font color="blue">product testing</font> or delivery, cost overruns or other problems     that <font color="blue">could seriously hurt</font> our business</td>
    </tr>
    <tr>
      <td>-18-       _________________________________________________________________    [66]Table of <font color="blue">Contents       </font>We may experience delays in the <font color="blue">development</font> of our <font color="blue">product <font color="blue">candidates</font></font> if the     third-party  <font color="blue"><font color="blue">manufacture</font>rs</font>  of  our <font color="blue">product <font color="blue">candidates</font></font> cannot meet FDA     <font color="blue">requirements</font> relating to <font color="blue">Good Manufacturing Practices</font></td>
    </tr>
    <tr>
      <td>Our third-party <font color="blue"><font color="blue">manufacture</font>rs</font> are required to produce our product     <font color="blue">candidates</font> under FDA current <font color="blue">Good Manufacturing Practices</font> in order to meet     acceptable standards for our <font color="blue"><font color="blue">clinical trial</font>s</font></td>
    </tr>
    <tr>
      <td>If <font color="blue">such standards</font> change, the     ability of third-party <font color="blue"><font color="blue">manufacture</font>rs</font> to produce our <font color="blue">product <font color="blue">candidates</font></font> on     the  schedule  we  require for our <font color="blue"><font color="blue">clinical trial</font>s</font> may be affected</td>
    </tr>
    <tr>
      <td>In     addition, third-party <font color="blue"><font color="blue">manufacture</font>rs</font> may not perform their <font color="blue">obligations</font> under     their <font color="blue">agreement</font>s with us or <font color="blue">may discontinue</font> their business before the time     required by us to <font color="blue">gain approval</font> for or <font color="blue">commercialize</font> our <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>Any <font color="blue">difficulties</font> or delays in the <font color="blue">manufacturing</font> and supply of our product     <font color="blue">candidates</font> could increase our costs or cause us to <font color="blue">lose revenue</font> or postpone     or cancel <font color="blue"><font color="blue">clinical trial</font>s</font></td>
    </tr>
    <tr>
      <td>The FDA also requires that we <font color="blue">demonstrate</font> structural and functional     <font color="blue">comparability</font>  between  the  same  drug  product produced <font color="blue">by different</font>     third-party  <font color="blue"><font color="blue">manufacture</font>rs</font></td>
    </tr>
    <tr>
      <td><font color="blue">Because  </font>we  may  <font color="blue">use multiple sources</font> to     <font color="blue">manufacture</font> <font color="blue">Proellex and Androxal</font>, we may need to conduct <font color="blue">comparability</font>     studies to assess whether <font color="blue">manufacturing</font> changes have affected the product     safety, identity, purity or potency of any commercial <font color="blue">product candidate</font>     compared to the <font color="blue">product candidate</font> used in <font color="blue"><font color="blue">clinical trial</font>s</font></td>
    </tr>
    <tr>
      <td>If we are unable     to <font color="blue">demonstrate</font> <font color="blue">comparability</font>, the FDA could require us to conduct <font color="blue">additional</font>     clinical  trials,  which  would  be  expensive and <font color="blue">significant</font>ly delay     <font color="blue">commercialization</font> of our <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>We  rely  on  <font color="blue">third parties</font> to conduct <font color="blue"><font color="blue">clinical trial</font>s</font> for our product     <font color="blue">candidates</font>,  and  their  failure  to timely and properly perform their     <font color="blue">obligations</font> may result in costs and delays that <font color="blue">prevent us from</font> obtaining     <font color="blue">regulatory</font> approval or <font color="blue">successfully</font> commercializing our <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>We rely on independent <font color="blue">contractors</font>, including researchers at clinical     research  <font color="blue">organizations</font>  and  <font color="blue">universities</font>,  in <font color="blue">certain areas</font> that are     <font color="blue"><font color="blue">particularly</font> relevant</font> to our research and product <font color="blue">development</font> plans, such as     the conduct of <font color="blue"><font color="blue">clinical trial</font>s</font></td>
    </tr>
    <tr>
      <td>Pharm-Olam International Ltd</td>
    </tr>
    <tr>
      <td>conducted our     previous <font color="blue">clinical trial</font> in Poland for Proellex for the treatment of uterine     fibroids and has been engaged to conduct our <font color="blue"><font color="blue">clinical trial</font>s</font> in the United     States for Proellex for <font color="blue">uterine fibroids</font> <font color="blue">and Androxal </font>for the treatment of     <font color="blue">testosterone</font> <font color="blue">deficiency</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">competition</font> for these <font color="blue">relationships</font> is intense,     and we may not be able to maintain our <font color="blue">relationships</font> with them on acceptable     terms</td>
    </tr>
    <tr>
      <td><font color="blue">Independent </font><font color="blue">contractors</font> generally may terminate their <font color="blue">engagements at</font>     any time, subject to notice</td>
    </tr>
    <tr>
      <td>As a result, we can control their <font color="blue">activities</font>     only within certain limits, and they will devote only a certain amount of     their time conducting research on and trials of our <font color="blue">product <font color="blue">candidates</font></font> and     assisting in developing them</td>
    </tr>
    <tr>
      <td>If they do not <font color="blue">successfully</font> carry out their     <font color="blue">duties under</font> their <font color="blue">agreement</font>s with us, fail to <font color="blue">inform us</font> if these trials     fail to <font color="blue">comply with</font> <font color="blue">clinical trial</font> protocols, or fail to meet expected     <font color="blue">deadlines</font>,  our  clinical  trials  may need to be extended, delayed or     terminated</td>
    </tr>
    <tr>
      <td>We may not be able to <font color="blue">enter into</font> <font color="blue">replacement</font> <font color="blue"><font color="blue">arrangement</font>s</font>     <font color="blue">without undue delays</font> or excessive <font color="blue">expenditures</font></td>
    </tr>
    <tr>
      <td>If there are delays in     testing or <font color="blue">regulatory</font> approvals as a result of the failure to perform by our     independent <font color="blue">contractors</font> or other <font color="blue">outside parties</font>, our drug <font color="blue">development</font> costs     <font color="blue">will increase</font> and we may not be able to attain <font color="blue">regulatory</font> approval for or     <font color="blue">successfully</font> <font color="blue">commercialize</font> our <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>Our <font color="blue"><font color="blue">liability</font> insurance may</font> not <font color="blue">provide adequate coverage nor may</font> it always     be <font color="blue">available on</font> favorable terms or at all</td>
    </tr>
    <tr>
      <td>Proellex, Androxal and the <font color="blue">phentolamine</font>-based product family have not     <font color="blue">been approved</font> for <font color="blue">commercial sale</font></td>
    </tr>
    <tr>
      <td>However, the current and future use of     our  <font color="blue">product <font color="blue">candidates</font></font> by us and potential corporate <font color="blue">collaborators</font> in     <font color="blue"><font color="blue">clinical trial</font>s</font>, and the sale of any <font color="blue">approved products</font> in the future, may     expose  us to <font color="blue">liability</font> claims</td>
    </tr>
    <tr>
      <td>These claims might be made <font color="blue">directly by</font>     consumers or <font color="blue">healthcare providers</font> or in<font color="blue">directly by</font> <font color="blue">pharmaceutical</font> companies,     potential corporate <font color="blue">collaborators</font> or <font color="blue">others selling such products</font></td>
    </tr>
    <tr>
      <td>We may     experience <font color="blue">financial losses</font> in the future due to product <font color="blue">liability</font> claims</td>
    </tr>
    <tr>
      <td>We have obtained limited general commercial <font color="blue">liability</font> <font color="blue">insurance coverage</font> for     our <font color="blue"><font color="blue">clinical trial</font>s</font></td>
    </tr>
    <tr>
      <td>We intend to expand our <font color="blue">insurance coverage</font> to include     the sale of <font color="blue">commercial products</font> if we obtain <font color="blue">marketing approval</font> for any of     our <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>However, we may not be able to maintain insurance     <font color="blue">coverage at</font> a <font color="blue">reasonable cost</font> or in <font color="blue">sufficient amounts</font> to <font color="blue">protect us against</font>     losses</td>
    </tr>
    <tr>
      <td>If a successful product <font color="blue">liability</font> claim or series of claims is     brought against us for uninsured <font color="blue">liabilities</font> or for <font color="blue">liabilities</font> in excess of     our <font color="blue">insurance limits</font>, our <font color="blue">assets may</font> not be sufficient to <font color="blue">cover such</font> claims     and our business <font color="blue">operations</font> could be impaired</td>
    </tr>
    <tr>
      <td>We face <font color="blue">significant</font> <font color="blue"><font color="blue">competition</font> with</font> many <font color="blue">companies with <font color="blue">substantially</font></font>     <font color="blue">greater <font color="blue">resources than</font></font> we have and other <font color="blue">possible advantages</font></td>
    </tr>
    <tr>
      <td>We are engaged in bio<font color="blue">pharmaceutical</font> product <font color="blue">development</font>, an industry     that is <font color="blue">characterized by</font> extensive <font color="blue">research efforts</font> and rapid <font color="blue">technological</font>     progress</td>
    </tr>
    <tr>
      <td>The bio<font color="blue">pharmaceutical</font> industry is also highly <font color="blue">competitive</font></td>
    </tr>
    <tr>
      <td>Our     <font color="blue">success will depend on</font> our ability to acquire, develop and <font color="blue">commercialize</font>     products and our ability to establish and maintain markets for any products     for which we receive <font color="blue">marketing approval</font></td>
    </tr>
    <tr>
      <td><font color="blue">Potential </font><font color="blue">competitors</font> in North     America,  Europe and elsewhere include major <font color="blue">pharmaceutical</font> companies,     specialty <font color="blue">pharmaceutical</font> companies and bio<font color="blue">technology</font> firms, <font color="blue">universities</font> and     other research <font color="blue">institutions</font> and <font color="blue">government</font> agencies</td>
    </tr>
    <tr>
      <td>Many of our <font color="blue">competitors</font>     have  <font color="blue">substantially</font>  greater  research  and <font color="blue">development</font> and <font color="blue">regulatory</font>     <font color="blue">capabilities</font>  and  experience,  and  <font color="blue">substantially</font> greater <font color="blue">management</font>,     <font color="blue">manufacturing</font>, <font color="blue">distribution</font>, marketing and financial resources, than we do</td>
    </tr>
    <tr>
      <td>Accordingly, our <font color="blue">competitors</font> may:                                        -19-       _________________________________________________________________    [67]Table of <font color="blue">Contents       </font>  •   develop or <font color="blue">license products</font> or other novel <font color="blue">technologies</font> that are more     <font color="blue">effective</font>, safer or <font color="blue">less costly than</font> the <font color="blue">product <font color="blue">candidates</font></font> that we are     developing;         •   obtain <font color="blue">regulatory</font> approval for products before we do; or         •   commit more <font color="blue">resources than</font> we can to developing, marketing and selling     <font color="blue">competing products</font></td>
    </tr>
    <tr>
      <td>The  main  therapeutic products <font color="blue">competitive</font> with Proellex for the     treatment of <font color="blue">uterine fibroids</font> and <font color="blue">endometriosis</font> are GnRH agonists, including     Lupron, which is <font color="blue">marketed by</font> <font color="blue">TAP Pharmaceuticals</font></td>
    </tr>
    <tr>
      <td>There are <font color="blue">additional</font>     companies developing similar progesterone-blocking <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>Asoprisnil,     an anti-progestin being developed by <font color="blue">TAP Pharmaceuticals</font> in <font color="blue">partnership</font> with     Schering AG, is currently in <font color="blue">Phase III </font><font color="blue"><font color="blue">clinical trial</font>s</font></td>
    </tr>
    <tr>
      <td><font color="blue">TAP Pharmaceuticals</font>     is a much <font color="blue">larger <font color="blue">company than</font></font> we are <font color="blue">with greater resources</font> and greater     ability to promote their <font color="blue">products than</font> we currently have</td>
    </tr>
    <tr>
      <td>In addition,     <font color="blue">surgical treatment</font> of both <font color="blue">uterine fibroids</font> and <font color="blue">endometriosis</font> competes with     Proellex by removing <font color="blue">uterine fibroids</font> and <font color="blue">by removing misplaced tissue</font> in     women with <font color="blue">endometriosis</font></td>
    </tr>
    <tr>
      <td>Our main <font color="blue">competitors</font> for the treatment of <font color="blue">testosterone</font> <font color="blue">deficiency</font> are     the <font color="blue">testosterone</font> <font color="blue">replacement</font> therapies currently being marketed</td>
    </tr>
    <tr>
      <td>The current     standard  of  care  is  Androgel, a topical gel for the <font color="blue">replacement</font> of     <font color="blue">testosterone</font> developed by Solvay Pharmaceuticals</td>
    </tr>
    <tr>
      <td>Solvay is a much larger     <font color="blue">company than</font> we are <font color="blue">with greater resources</font> and <font color="blue">marketing ability</font></td>
    </tr>
    <tr>
      <td><font color="blue">Androxal     </font><font color="blue">would also compete with</font> other forms of <font color="blue">testosterone</font> <font color="blue">replacement</font> therapies     such as oral <font color="blue">treatments</font>, patches, injectables and a <font color="blue">tablet applied</font> to the     upper gum</td>
    </tr>
    <tr>
      <td>There is another topical gel currently <font color="blue">marketed by</font> Auxilium     Pharmaceuticals called Testim, and a transdermal patch <font color="blue">marketed by</font> Watson     Pharmaceuticals called AndroDerm</td>
    </tr>
    <tr>
      <td>There can be no assurance that our product     <font color="blue">candidates</font> will be more successful than <font color="blue">competitive</font> products</td>
    </tr>
    <tr>
      <td>In addition,     other potential <font color="blue">competitors</font> may be developing <font color="blue">testosterone</font> therapies similar     to ours</td>
    </tr>
    <tr>
      <td>The <font color="blue">erectile dysfunction market</font> is <font color="blue">well established</font> and intensely     <font color="blue">competitive</font></td>
    </tr>
    <tr>
      <td>Our main <font color="blue">competitors</font> are <font color="blue">already existing products such as</font>     Viagra^®, which is <font color="blue">marketed by</font> Pfizer; Levitra^®, which is being <font color="blue">marketed by</font>     <font color="blue">Bayer AG </font>outside the <font color="blue">United States </font>and GlaxoSmithKline and Schering-Plough     Corporation <font color="blue">in the United States</font>; and Cialis, which is being <font color="blue">marketed by</font>     Icos Lilly</td>
    </tr>
    <tr>
      <td>In addition, there are several other <font color="blue">bio<font color="blue">pharmaceutical</font> companies</font>     that are also developing products that <font color="blue">would directly compete with</font> our     <font color="blue">phentolamine</font>-based products</td>
    </tr>
    <tr>
      <td>We are <font color="blue">thinly staffed</font> and <font color="blue">highly dependent on</font> a limited number of <font color="blue">management</font>     persons and <font color="blue">key personnel</font>, and if we lose these members of our team or are     unable to attract and retain <font color="blue">additional</font> <font color="blue">qualified personnel</font>, our future     growth and ability to <font color="blue">compete would suffer</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">competition</font> for <font color="blue">qualified personnel</font> in the bio<font color="blue">pharmaceutical</font> field     is intense, and our <font color="blue">future success depends upon</font> our ability to attract,     retain and motivate highly skilled scientific, technical and managerial     employees</td>
    </tr>
    <tr>
      <td>We have only 6 full-time employees at the present time, including     our President and CEO, Joseph S Podolski, and our Vice President, Business     Development  and  CFO,  Louis  Ploth,  Jr</td>
    </tr>
    <tr>
      <td>We are <font color="blue">highly dependent on</font>     Messrs</td>
    </tr>
    <tr>
      <td><font color="blue">Podolski  </font>and  Ploth for the <font color="blue">management</font> of our company and the     <font color="blue">development</font>  of our <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td><font color="blue">Both Messrs</font></td>
    </tr>
    <tr>
      <td>Podolski and Ploth have     employment <font color="blue">agreement</font>s with us</td>
    </tr>
    <tr>
      <td>Podolski and Ploth will remain with us through <font color="blue">development</font> of our     current <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>We do not maintain key person <font color="blue">life insurance on</font>     any of our directors, officers or employees</td>
    </tr>
    <tr>
      <td><font color="blue">Podolski or Mr</font></td>
    </tr>
    <tr>
      <td>Ploth <font color="blue">could delay</font> or curtail our research and product     <font color="blue">development</font> efforts</td>
    </tr>
    <tr>
      <td>Additionally, in order to <font color="blue">commercialize</font> our products <font color="blue">successfully</font>, we     will be required to expand our workforce, <font color="blue">particularly</font> in the areas of     <font color="blue"><font color="blue">clinical trial</font>s</font> <font color="blue">management</font>, <font color="blue">regulatory</font> affairs, business <font color="blue">development</font>, sales     and marketing and <font color="blue">administrative</font> and <font color="blue">accounting functions</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">activities</font>     will require the addition of <font color="blue">new personnel</font> and the <font color="blue">development</font> of <font color="blue">additional</font>     expertise  by  <font color="blue">management</font></td>
    </tr>
    <tr>
      <td>We  face intense <font color="blue">competition</font> for qualified     individuals from numerous <font color="blue">bio<font color="blue">pharmaceutical</font> companies</font>, as well as academic     and  other research <font color="blue">institutions</font></td>
    </tr>
    <tr>
      <td>Our intention is to hire up to seven     <font color="blue">employees over</font> the <font color="blue">next two years</font></td>
    </tr>
    <tr>
      <td>To the extent we are not able to attract     and  retain  employees  on  favorable terms; we <font color="blue">may face delays</font> in the     <font color="blue">development</font> or <font color="blue">commercialization</font> of our <font color="blue">product <font color="blue">candidates</font></font> and extensive     costs in retaining <font color="blue">current employees</font> or searching for and <font color="blue">training new</font>     employees</td>
    </tr>
    <tr>
      <td>Our plan to use <font color="blue"><font color="blue">collaboration</font>s</font> to leverage our <font color="blue">capabilities</font> may not be     successful</td>
    </tr>
    <tr>
      <td>As part of our business strategy, we intend to <font color="blue">enter into</font> <font color="blue">collaboration</font>     <font color="blue"><font color="blue">arrangement</font>s</font>  <font color="blue">with strategic partners</font> to develop and <font color="blue">commercialize</font> our     <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>For our <font color="blue">collaboration</font> efforts to be successful, we must     identify  partners  whose  <font color="blue">competencies</font>  <font color="blue">complement ours</font></td>
    </tr>
    <tr>
      <td>We must also     <font color="blue">successfully</font>  enter  into  <font color="blue">collaboration</font> <font color="blue">agreement</font>s with them on terms     attractive  to  us  and  integrate  and coordinate their resources and     <font color="blue">capabilities</font>  with  our  own</td>
    </tr>
    <tr>
      <td>We may be <font color="blue">unsuccessful</font> in <font color="blue">entering into</font>     <font color="blue">collaboration</font> <font color="blue">agreement</font>s with acceptable partners or <font color="blue">negotiating</font> favorable     terms  in these <font color="blue">agreement</font>s</td>
    </tr>
    <tr>
      <td>In addition, we may face a <font color="blue">disadvantage</font> in     seeking to <font color="blue">enter into</font> or <font color="blue">negotiating</font> <font color="blue"><font color="blue">collaboration</font>s</font> with potential partners     because  other potential <font color="blue">collaborators</font> may have greater <font color="blue">management</font> and     financial <font color="blue">resources than</font> we do</td>
    </tr>
    <tr>
      <td>Also, we may be <font color="blue">unsuccessful</font> in <font color="blue">integrating</font>     the resources or <font color="blue">capabilities</font> of these <font color="blue">collaborators</font></td>
    </tr>
    <tr>
      <td>In addition, our     <font color="blue">collaborators</font> may prove difficult to work with or <font color="blue">less skilled than</font> we     <font color="blue">originally</font> expected</td>
    </tr>
    <tr>
      <td>If we are <font color="blue">unsuccessful</font> in our <font color="blue">collaborative</font> efforts,     our ability to develop and market <font color="blue">product <font color="blue">candidates</font></font> could be severely     limited</td>
    </tr>
    <tr>
      <td>-20-       _________________________________________________________________    [68]Table of <font color="blue">Contents       </font>Healthcare reform measures could <font color="blue">adversely affect</font> our business</td>
    </tr>
    <tr>
      <td>The business and <font color="blue">financial condition</font> of <font color="blue">pharmaceutical</font> companies are     <font color="blue">affected by</font> the efforts of <font color="blue"><font color="blue">government</font>al</font> and third-party payers to contain or     reduce  the  costs  of healthcare</td>
    </tr>
    <tr>
      <td>In the <font color="blue">United States </font>and in foreign     <font color="blue">jurisdictions there</font> have been, and we expect that <font color="blue">there will continue</font> to be,     a number of <font color="blue">legislative</font> and <font color="blue">regulatory</font> proposals aimed at changing the     <font color="blue">healthcare system</font></td>
    </tr>
    <tr>
      <td>For example, in some countries other than the United     States, pricing of <font color="blue">prescription</font> drugs is subject to <font color="blue">government</font> control, and     we expect proposals to implement similar controls in the <font color="blue">United States </font>to     continue</td>
    </tr>
    <tr>
      <td>The pendency or approval of <font color="blue">such proposals could</font> result in a     decrease in our stock price or limit our ability to <font color="blue">raise capital</font> or to     obtain strategic <font color="blue"><font color="blue">collaboration</font>s</font> or licenses</td>
    </tr>
    <tr>
      <td>We <font color="blue">face high volatility</font> in our stock price</td>
    </tr>
    <tr>
      <td>We are a <font color="blue">development</font> stage company and the <font color="blue">market prices</font> for securities     of  <font color="blue">development</font> companies in the bio<font color="blue">technology</font> sector have been highly     volatile and <font color="blue">may continue</font> to be very volatile in the future</td>
    </tr>
    <tr>
      <td>The  <font color="blue">following listed factors as well as</font> other <font color="blue">factors may</font> have a     <font color="blue">significant</font> impact on the price of our <font color="blue">common stock</font>:       •   <font color="blue">announcements</font> of <font color="blue">technology</font> innovations and <font color="blue">new products</font> developed by     other <font color="blue">competitors</font>;         •   <font color="blue">development</font>s relating to <font color="blue">proprietary</font> rights and patents;         •   publicity relating to actual or <font color="blue">potential medical</font> results relating to     products under <font color="blue">development</font> or being <font color="blue">commercialize</font>d by our other <font color="blue">competitors</font>;         •   <font color="blue">regulatory</font> <font color="blue">development</font>s <font color="blue">concerning</font> our products in the <font color="blue">United States </font>    and foreign countries;         •   issues <font color="blue">concerning</font> the safety of our products in <font color="blue">development</font> or similar     products being developed by our <font color="blue">competitors</font>; and         •   economic and other <font color="blue">external factors</font> or a disaster or crisis</td>
    </tr>
  </tbody>
</table>